The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study
Principal Investigator
John SwistonOverview
Body Locations and Systems
Pulmonary HypertensionClinicalTrials.gov#
NCT02558231Status
Closed for RecruitmentStudy Start/End
Feb 24, 2016 to Jan 30, 2020Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Mami Okada, Research Coordinator Phone
604-875-4111 ext.69831 Email Address
mami.okada@vch.caPurpose of Study
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.